Histidine‐Rich Glycoprotein Alleviates Liver Ischemia/Reperfusion Injury in Mice With Nonalcoholic Steatohepatitis

Jie Guo, Tomohiko Akahoshi, Yukie Mizuta, Masaharu Murata, Sayoko Narahara, Takahito Kawano, Yoshihiro Nagao, Shuo Zhang, Morimasa Tomikawa, Hirofumi Kawanaka, Makoto Hashizume – 1 December 2020 – Hepatic ischemia/reperfusion injury (IRI) is a major complication of liver surgery and transplantation, especially in patients with nonalcoholic steatohepatitis (NASH). The mechanism of NASH susceptibility to IRI has not been fully clarified. We investigated the role of liver‐produced histidine‐rich glycoprotein (HRG) in NASH IRI.

Liver Transplantation for Acute Intermittent Porphyria

Mattias Lissing, Greg Nowak, René Adam, Vincent Karam, Alexander Boyd, Laurent Gouya, Wouter Meersseman, Espen Melum, Urszula Ołdakowska‐Jedynak, Florian P. Reiter, Jordi Colmenero, Rosario Sanchez, Uta Herden, Janneke Langendonk, Paolo Ventura, Helena Isoniemi, Olivier Boillot, Felix Braun, Stéphanie Perrodin, Elizabeth Mowlem, Staffan Wahlin, European Liver and Intestine Transplant Association – 1 December 2020 – Recurrent attacks of acute intermittent porphyria (AIP) result in poor quality of life and significant risks of morbidity and mortality.

Clinicopathologic Characteristics of Centrilobular Injury in Pediatric Liver Transplantation

Iván A. González, Hsiang‐Chih Lu, Zahra Alipour, Sakil S. Kulkarni, Janis M. Stoll, Kim H.H. Liss, Louis P. Dehner, Mai He – 30 November 2020 – Centrilobular injury (CLI) is defined as the presence of perivenular mononuclear inflammation, hepatocyte dropout, and extravasated erythrocytes. In pediatric liver allografts, CLI has been associated with advanced fibrosis and chronic rejection (CR). We sought to better characterize the clinicopathologic features of CLI in the setting of T cell–mediated rejection (TCMR) and its association with complement component 4d (C4d) deposition.

A Multicentric Experience on Living Donor Liver Transplantation in Coronavirus Disease 2019 Hotspots in India

Joy Varghese, Selvakumar Malleeswaran, Rajanikanth V. Patcha, Ellango Appusamy, Perumal Karnan, Dharmesh Kapoor, Kota Venugopal, Chandhan Kumar Kedarisetty, Balbir Singh, Prashantha S. Rao, Raghavendra Babu Yalakanti, Ravi Mohanka, Anurag Shrimal, Vinayak Nikam, Karan Kumar, Sunil D. Shenvi, Bhaskaran Pillai Venugopal, Nigel D. Heaton – 30 November 2020

Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria

Prashant Bhangui, Sanjiv Saigal, Dheeraj Gautam, Tarun Piplani, Narendra Choudhary, Rohan Chaudhary, Sanjay Yadav, S. Thiagarajan, Amit Rastogi, Neeraj Saraf, Samiran Nundy, A.S. Soin – 30 November 2020 – Conventional selection criteria for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) are based on tumour size/number only, and do not consider vital surrogates of tumor biology such as alpha‐fetoprotein (AFP) and tumor [18F]fluorodeoxyglucose positron emission tomography ([18F]FDG PET) avidity.

Human Nonalcoholic Steatohepatitis on a Chip

May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, Ermanno Gherardi, Shiladitya Sengupta, Hae Lin Jang – 29 November 2020 – Nonalcoholic steatohepatitis (NASH), an advanced stage of nonalcoholic fatty liver disease (NAFLD), is a rapidly growing and global health problem compounded by the current absence of specific treatments. A major limiting factor in the development of new NASH therapies is the absence of models that capture the unique cellular structure of the liver microenvironment and recapitulate the complexities of NAFLD progression to NASH.

Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure

Philip R. Spradling, Yuna Zhong, Anne C. Moorman, Loralee B. Rupp, Mei Lu, Stuart C. Gordon, Eyasu H. Teshale, Mark A. Schmidt, Yihe G. Daida, Joseph A. Boscarino, for the Chronic Hepatitis Cohort Study (CHeCS) Investigators – 29 November 2020 – There are limited data examining the relationship between psychosocial factors and receipt of direct‐acting antiviral (DAA) treatment among patients with hepatitis C in large health care organizations in the United States. We therefore sought to determine whether such factors were associated with DAA initiation.

Immunosuppressive Drug‐Resistant Armored T‐Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients

Morteza Hafezi, Meiyin Lin, Adeline Chia, Alicia Chua, Zi Zong Ho, Royce Fam, Damien Tan, Joey Aw, Andrea Pavesi, Thinesh Lee Krishnamoorthy, Wan Cheng Chow, Wenjie Chen, Qi Zhang, Lu‐En Wai, Sarene Koh, Anthony T. Tan, Antonio Bertoletti – 29 November 2020

Subscribe to